Towa International welcomes the visit of Minister Jordi Hereu and reinforces the strategic role of generic medicines in the sustainability of Spain’s National Health System
- The Japanese company highlights its industrial commitment in Spain as an international hub for Europe and the United States
- The visit underscored the importance of public–private collaboration in ensuring access to essential medicines and strengthening the resilience of the healthcare system
Barcelona, 27 April 2026. – The Minister for Industry and Tourism, Jordi Hereu, visited the headquarters of Towa International, the international hub of Towa Pharmaceutical and a company specialising in the research, development, manufacture and distribution of generic medicines, during a visit focused on the strategic role of the generic pharmaceutical industry.
The day’s programme included a tour of the laboratory, pilot plant and production facility in Martorelles, Barcelona, where Towa International demonstrated how it integrates innovation, sustainability and industrial efficiency into its processes. During the visit, the main challenges facing the sector were also discussed, including the sustainability of the healthcare system, industrial competitiveness and the need to continue strengthening the generic medicines supply chain.
David Peix, CEO of Towa International, said: “It has been an honour to welcome Minister Jordi Hereu to our headquarters. This visit has also provided an opportunity to highlight the strategic role of generic medicines for the Spanish National Health Service (SNS) and to showcase our industrial capabilities. Furthermore, the meeting between our investors and the minister has allowed us to convey first-hand the strategic commitment the group has made to Spain: it is not just a dot on the map, but the gateway to our vision of international expansion from here.”
Spain, a strategic hub for international expansion
During the meeting, Towa International also outlined the group’s global vision and its commitment to Spain as a strategic hub for production, innovation and internationalisation. With its international headquarters in Barcelona, the company acts as a hub for Europe and the United States, reinforcing Spain’s position as an industrial and technological centre within the pharmaceutical sector.
This commitment is underpinned by the country’s strengths in terms of talent, infrastructure and technological development – key factors that led the Japanese group to establish its international hub in Spain in 2020, consolidating it as a strategic platform for its global growth. Since its foundation, Towa International has reinforced this commitment by creating more than 150 jobs.
Towa Pharmaceutical employs 3,770 people in Japan and has an annual production capacity of over 34.5 billion units, reflecting the group’s international reach and its ability to meet the needs of the pharmaceutical market on a large scale. Towa International, meanwhile, employs over 1,080 people in Spain, Italy, Portugal and the United States, and has an annual production capacity of more than 6 trillion doses at its plant in Barcelona.
Investment, innovation and production from Barcelona
Since its establishment in 2020, Towa International has invested over €165 million in the modernisation of its facilities and in R&D projects, consolidating its Barcelona headquarters as a leading centre for the production, development and internationalisation of generic medicines.
Through its subsidiary Towa2B, which encompasses the CMO/CDMO business line, the company operates in more than 40 countries and manufactures essential medicines, helping to meet growing healthcare needs while diversifying its portfolio across different markets.
